Supplemental Table 1. Clinical and epidemiological characteristics of the
|
|
- Kerry Bates
- 5 years ago
- Views:
Transcription
1 Tendeiro et al. Supplemental Digital Content 1_ Page 2 of 1 Supplemental Table 1. Clinical and epidemiological characteristics of the therapy naïve and treated infected individuals. a Number [male/female] 16 [6/1] 28 [9/19] 1 [5/5] ge, years 44 (27-57) 54 (19-78) 57 (34-62)** Caucasian/black 15/1 15/13 6/4 CD4 + T-cells, % 59 (4-77) 4 (1-66) ** 26 (4-4) ***/## CD4 + T-cells/μl 818 ( ) 553 ( ) * 288 (84-554) ***/## Viremia, HIV RN cp/ml - 2 ( ) 2 ( ) Proviral DN, cp/1 6 PMC - 5 (5-133) 13 (5-726) -cells, % 6 (3-13) 6 (3-2) 1 (4-17) * -cells/μl 12 (63-369) 131 (3-369) 135 (63-313) Data are expressed as median, with limits in brackets. Statistical analysis was performed with Mann-Whitney tests. * P<.5; ** P<.1; *** P<.1 in comparison with seronegatives. ## P<.1 for comparisons between infected cohorts. a RT regimens were as follows (number of patients): 3TC+ZT+LPV/r (3); 3TC+d4T+SQV/r (2); 3TC/ZT+IDV/r (1); 3TC+ZT+IDV (1); C+3TC+ZT (3). Nucleoside analog reverse transcriptase inhibitors (NRTIs): ZT Zidovudine, 3TC- Lamivudine, C- abacavir, d4t- Stavudine, r- ribavirine. Protease inhibitors (PIs)- LPV- Lopinavir, IDV- Indinavir, SQV- Saquinavir.
2 Tendeiro et al. Supplemental Digital Content 1_ Page 3 of 1 Supplemental Table 2. Relationship between absolute counts of circulating -cell populations and markers of disease progression in the and cohorts. -cells/μl Total -cells/μl CD27 neg IgD + CD27 + CD27 + IgD + CD27 + IgD neg (n=38) CD4 + T-cells/µl.3522; ; ;<.1.783;< ;<.1 Viremia, HIV RN cp/ml -.754; ; ; ; ;.74 %HL-DR + CD38 + within CD4 a.153; ; ; ; ;.36 %HL-DR + CD38 + within CD8 a -.39; ; ; ; ;.93 β2-microglobulin (mg/l) b -.211; ; ;< ;< ;.2 (n=2) CD4 + T-cells/µl.2144; ; ; ; ;.362 Viremia, HIV RN cp/ml.98; ; ; ; ;.3914 %HL-DR + CD38 + within CD4 a -.256; ; ; ; ;.6932 %HL-DR + CD38 + within CD8 a -.669; ; ; ; ;.1736 β2-microglobulin (mg/l) b -.374; ; ; ; ;.9286 Spearman s correlation coefficient was used and results are expressed as R;P, with significant correlations in bold. a Frequency of cells co-expressing the activation markers HL-DR and CD38 within CD4 + and CD8 + T-cells (median, range) : 3.4%, % (CD4), and 15.1%, % (CD8); untreated : 5.5%, % (CD4), and 23.7%, % (CD8). No significant differences were found between infected cohorts, which exhibited significantly higher levels than seronegative controls (CD4: 1.1%,.7-2.%; CD8: 2.7%, %). b β2-microglobulin serum levels were assessed for 3 (median: 2.6 mg/l, range: mg/l) and 14 (median: 2.4 mg/l, range: mg/l) infected individuals, with no statistically significant differences being observed between cohorts.
3 Tendeiro et al. Supplemental Digital Content 1_ Page 4 of 1 Supplemental Table 3. Clinical and epidemiological characteristics of the and cohorts stratified according to degree of CD4 + T-cell depletion. >35 CD4 + /µl <35 CD4 + /µl >35 CD4 + /µl <35 CD4 + /µl Number [male/female] 16 [6/1] 22 [7/15] 16 [7/9] 1 [7/3] 1 [8/2] ge, years 44 (27-57) 56 (28-78) * 51 (19-63) 41 (27-61) 35 (23-49) # Caucasian/black 15/1 13/9 8/8 1/ 5/5 CD4 + T-cells, % 59 (4-77) 45 (22-66) **/ (4-32) *** 46 (17-74) * 14 (2-32) ***/+++ CD4 + T-cells/μl 818 ( ) 661 ( ) (52-344) *** 885 ( ) 298 (18-344) ***/+++ Viremia (HIV RN cp/ml) - 2 ( ) 2 ( ) 5x1 3 (4-19x1 3 ) 5x1 5 (71-447x1 3 ) ++/## Proviral DN (cp/1 6 PMC) - 78 (5-133) 57 (5-12) 81 (5-573) 41 (5-975) -cells, % 6 (3-13) 7 (3-17) 6 (3-2) 5 (2-11) 6 (2-16) -cells/μl 12 (63-369) 141 (52-357) 1 (3-369) 118 (56-46) 117 (33-267) Data are expressed as median, with limits in brackets. Statistical analysis was performed with Mann-Whitney tests. * P<.5; ** P<.1; *** P<.1 in comparison with seronegatives. ++ P<.1; +++ P<.1 in comparison with the reciprocal subgroup (>35 versus <35). # P<.5; ## P<.1 for comparisons between infected cohorts.
4 Tendeiro et al. Supplemental Digital Content 1_ Page 5 of 1 Supplemental Table 4. Clinical and epidemiological characteristics of the and cohorts stratified according to viremia status. Number [male/female] 16 [6/1] 28 [9/19] 1 [5/5] 3 [2/1] 17 [13/4] ge, years 44 (27-57) 56 (28-78) 52 (19-62) 47 (3-61) 38 (23-59) Caucasian/black 15/1 17/11 4/6 3/ 12/5 CD4 + T-cells, % 59 (4-77) 37 (13-66) ***/+ 24 (4-53) *** 6 (59-74) # 27 (2-56) ***/++ CD T-cells/μl ( ) ( ) */+ (84-596) *** ( ) ( ) ** Viremia (HIV RN cp/ml) - <2 7.6x1 3 ( ) <4 1.9x1 4 (71-447x1 3 ) Proviral DN (cp/1 6 PMC) - 5 (5-133) (5-12) 14 (5-324) 53 (5-975) -cells, % 6 (3-13) 7 (3-17) 7 (3-2) 1 (4-11) 6 (2-16) -cells/μl 12 (63-369) 135 (37-357) 131 (3-369) 125 (92-324) 111 (33-46) Data are expressed as median, with limits in brackets. Statistical analysis was performed with Mann-Whitney tests. * P<.5; ** P<.1; *** P<.1 in comparison with seronegatives. + P<.5; ++ P<.1 in comparison with the reciprocal subgroup ( versus ). # P<.5 for comparisons between infected cohorts.
5 CD27 + IgD + -cells/ l CD27 + IgD + -cells/ l CD27 + IgD neg -cells/ l CD27 + IgD neg -cells/ l CD27 + -cells/ l CD27 + -cells/ l Tendeiro et al. Supplemental Digital Content 1_ Page 6 of <.1 < <.1 < <.1 < Seroneg Seroneg >35 <35 Supplemental Figure 1. bsolute numbers of memory -cell subsets in infected individuals. () Circulating numbers of total memory cells (CD27 + ), switched memory cells (CD27 + IgD neg ) and unswitched memory cells (CD27 + IgD + ) in infected, as well as seronegative (Seroneg) and + individuals. () + patients were further subdivided according to disease stage (early: >35 CD4 + T-cells/µl; late: <35 CD4 + T-cells/µl) and levels of plasma viral load (aviremic: undetectable plasma viral load; viremic: detectable) and the absolute counts of memory cell populations are shown. Each dot represents one individual and bars indicate median. Statistical analysis was performed using the Mann-Whitney test and significant P values are shown.
6 Tendeiro et al. Supplemental Digital Content 1_ Page 7 of <.1 < % CD % CD27 + IgD neg < C <.1 < % CD27 + IgD + 3 < >35 <35 >35 <35 Supplemental Figure 2. -cell disturbances in as compared to groups of infected patients stratified to disease stage and viremia status. Patients were divided according to disease stage (early: >35 CD4 + T-cells/µl; late: <35 CD4 + T-cells/µl) and levels of plasma viral load (aviremic: undetectable plasma viral load; viremic: detectable). Relative frequencies of () total memory cells (CD27 + ), () switched memory cells (CD27 + IgD neg ) and (C) unswitched memory cells (CD27 + IgD + ) within total -cells. Comparisons were made between seronegatives and all groups of infected individuals. Each dot represents one individual and bars indicate median. Statistical analysis was performed using the Mann-Whitney test and significant P values are shown.
7 Tendeiro et al. Supplemental Digital Content 1_ Page 8 of 1 8 < % CD % CD27 + IgD neg 8 6 < % CD27 + IgD + C 4 < < < >35 <35 >35 <35 Supplemental Figure 3. -cell disturbances in treated as compared to untreated infected patients stratified to disease stage and viremia status. Patients were divided according to disease stage (early: >35 CD4 + T-cells/µl; late: <35 CD4 + T-cells/µl) and levels of plasma viral load (aviremic: undetectable plasma viral load; viremic: detectable). Relative frequencies of () total memory cells (CD27 + ), () switched memory cells (CD27 + IgD neg ) and (C) unswitched memory cells (CD27 + IgD + ) within total -cells. Comparisons were made between seronegatives and all groups of infected individuals. Each dot represents one individual and bars indicate median. Statistical analysis was performed using the Mann-Whitney test and significant P values are shown.
8 rgp36 (S/CO) rpc2-c3 (S/CO) IgG (mg/dl) IgM (mg/dl) Ig (mg/dl) Tendeiro et al. Supplemental Digital Content 1_ Page 9 of Untreated Untreated Untreated Supplemental Figure 4. Serum levels of immunoglobulin and of specific antibodies against envelope glycoproteins gp125 and gp36. () Serum levels of total IgG, total IgM, and total Ig in untreated HIV+ and in RT-treated + patients. () Serum levels of specific antibodies against gp36 and gp125 expressed as OD clinical sample /OD cut-off (S/CO) ratios in + individuals. Each dot represents one individual. Patients with viremia below cut-off are shown as open dots and viremic patients as filled dots. Normal range of immunoglobulin values is represented by grey shading. Statistical analysis was performed using the Mann-Whitney test and significant P values are shown. ars represent median.
9 FF (pg/ml) FF (pg/ml) Tendeiro et al. Supplemental Digital Content 1_ Page 1 of >35 <35 >35 < >35 <35 >35 <35 Supplemental Figure 5. Serum FF levels in HIV infected individuals stratified to disease stage and viremia status. Patients were divided according to disease stage (early: >35 CD4 + T- cells/µl; late: <35 CD4 + T-cells/µl) and levels of plasma viral load (aviremic: undetectable plasma viral load; viremic: detectable). Comparisons were made between seronegatives and () groups of and infected individuals; () groups of untreated and treated infected individuals. Each dot represents one individual and bars indicate median. Statistical analysis was performed using the Mann-Whitney test and significant P values are shown.
PD-1 and its ligand PD-L1 are progressively up-regulated on CD4 and CD8 T-cells. in HIV-2 infection irrespective of the presence of viremia
Tendeiro et al_ Supplemental Digital ontent_page of PD and its ligand PDL are progressively upregulated on D4 and D8 Tcells in infection irrespective of the presence of viremia Supplemental Digital ontent
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationSupplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.
Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationI m B m. 1 f ub I B. D m B. f u. 1 f ua 1 D I A. I A m. D m A. f a. 1 f u. D m B ) D m A )(I m B. 1 f ua. 1 (I m A. log (I A. log f.
Supplementary Material Appendix 1 Here we show that independent inhibition by a single drug of two distinct steps (A and ) in the viral life cycle results in a non-linear median effect dose-response curve
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationBecause accurate and reproducible phenotypic susceptibility
BRIEF REPORT: CLINICAL SCIENCE Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays Jie Zhang, MS,* Soo-Yon Rhee, MS,* Jonathan Taylor, PhD, and
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationIgG3 regulates tissue-like memory B cells in HIV-infected individuals
SUPPLEMENTARY INFORMATION Articles https://doi.org/10.1038/s41590-018-0180-5 In the format provided by the authors and unedited. IgG3 regulates tissue-like memory B cells in HIV-infected individuals Lela
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationIndustry Request Integrase Inhibitors
Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationTHERAPEUTIC DRUG MONITORING (TDM) Table 2. Dose Adjustment. Patient Drug (mg) Symptoms C trough -fold increase compared to MEC WT
1 The Sixth International Congress on Drug Therapy in HIV Infection took place in Glasgow, UK, on November 17-21, 2002. Pharmacological aspects of antiretroviral therapy were covered in both oral and poster
More informationThe advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD
CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with
More informationThe impact of antiretroviral drugs on Cardiovascular Health
The impact of antiretroviral drugs on Cardiovascular Health José López-Sendón Hospital Universitario La Paz. IdiPaz Madrid. Spain Research grants and honoraria from (research committees, clinical trials,
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationVitamin D Deficiency in HIV: A Shadow on Long-Term Management?
AIDS Rev. 2014;16:59-74 (Supplementary Data) Vitamin D Deficiency in HIV: A Shadow on Long-Term Management? Chloe Orkin, et al.: Vitamin D deficiency in HIV (Supplementary Data) Chloe Orkin 1, David A.
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationAntiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa
Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationDepartment of General Medicine, Juntendo University School of Medicine, Tokyo; and 2
Jpn. J. Infect. Dis., 69, 33 38, 2016 Original Article Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naäƒve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot
More informationSupplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups
Supplemental Table S1: Unadjusted and Adjusted Hazard Ratios for Diabetes Associated with Baseline Factors Considered in Model 3 SMART Participants Only Unadjusted Adjusted* Baseline p-value p-value Covariate
More informationSupporting Information
Supporting Information Horwitz et al. 73/pnas.35295 A Copies ml - C 3NC7 7 697 698 7 7 73 76-2 2 Days Gp2 residue G458D G459D T278A 7/36 N28 K D 28 459 A28T ID# 697 ID# 698 ID# 7 ID# 7 ID# 73 ID# 76 ID#
More informationMajor Depletion of Plasmacytoid Dendritic Cells in HIV-2 Infection, an Attenuated Form of HIV Disease
Major Depletion of Plasmacytoid Dendritic Cells in HIV-2 Infection, an Attenuated Form of HIV Disease Rita Cavaleiro 1, António P. Baptista 1, Rui S. Soares 1, Rita Tendeiro 1, Russell B. Foxall 1, Perpétua
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationOverview of role of immunologic markers in HIV diagnosis
Overview of role of immunologic markers in HIV diagnosis Savita Pahwa, M.D. Departments of Microbiology & Immunology and Pediatrics University of Miami, Miller School of Medicine, Miami, Florida Background:
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationA Genetic Test to Screen for Abacavir Hypersensitivity Reactions
The Future of Pharmacogenetics in HIV Clinical Care A Genetic Test to Screen for Abacavir Hypersensitivity Reactions Evan Collins & Misty Bath CANAC/ACIIS 15 th Annual Conference Vancouver, BC April 2007
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationCombination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience
Antiviral Therapy 6: 201-229 Review Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience RPG van Heeswijk 1 *, AI Veldkamp
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationScottish Medicines Consortium
Scottish Medicines Consortium darunavir 300mg tablets (Prezista ) No. (378/07) Tibotec (a division of Janssen-Cilag Ltd) 4 May 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationDIVISION OF ANTIVIRAL DRUG PRODUCTS (HFD-530) MICROBIOLOGY REVIEW NDA:
Atazanavir (BMS-232632, ATV) Molecular Formula: C 38 H 52 N 6 O 7 H 2 SO 4 Molecular Weight: 704.9 Dosage Form(s): 100/150/200 mg capsule Route(s) of Administration: Oral Pharmacological Category: Indication(s):
More informationHIV - Life cycle. HIV Life Cyle
Human Immunodeficiency Virus Retrovirus - integrated into host genome ne single-strand RA 7,000 bases HIV1 > HIV2 > HIV0 Pathology Destruction of CD4+ T lymphocytes Loss of immune function pportunistic
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationDespite the wealth of efficacy data from
OPTIMIZING HIV DRUG THERAPY * John G. Bartlett, MD ABSTRACT The clinical success of highly active antiretroviral therapy (HAART) in the treatment of human immunodeficiency virus disease is one of the great
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationHIV epidemiology since HIV in the United States. HIV Transmission
HIV epidemiology since 1999 8% increase in HIV diagnoses Men who have sex with men (MSM) increased 14% Heterosexual increased 10% IVDU decrease about 30% Young Black MSM 15% incidence HIV in the United
More informationThe art of HAART: a practical approach to antiretroviral therapy
The art of HAART: a practical approach to antiretroviral therapy CATHERINE ORRELL MB ChB, MSc Clinical Trials Manager HIV Research Unit Somerset Hospital Cape Town Catherine Orrell completed her specialist
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationTOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY
SAFETY AND TOLERABILITY OF CURRENTLY AVAILABLE ANTIRETROVIRAL AGENTS * Esteban Martinez, MD, PhD ABSTRACT Safety and tolerability are important factors to consider when instituting or modifying therapy
More informationInteractive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1
Antiviral Therapy 10:551 555 Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1 Mina John, Corey B Moore, Ian R James and Simon A Mallal* Centre for Clinical
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More informationefigure 1: Process of identification and selection of studies for inclusion in the review
efigure 1: Process of identification and selection of studies for inclusion in the review 1 efigure 2: Publication bias in studies reporting incidence rate of diabetes mellitus in ART-experienced global
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationHIV-2 Therapy. Ricardo Jorge Camacho KU Leuven, Rega Institute for Medical Research, Leuven, Belgium
HIV-2 Therapy Ricardo Jorge Camacho KU Leuven, Rega Institute for Medical Research, Leuven, Belgium World distribution ~1.000.000 2.000.000 people infected in West Africa Highest prevalence : Guinea-Bissau
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationHIV Overview. Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program
HIV Overview Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program www.hivresearch.org 1 Outline HIV Virology, Transmission, and Pathogenesis
More informationAntiviral Chemotherapy
Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHigher Risk of Hyperglycemia in HIV-Infected Patients Treated with Didanosine Plus Tenofovir
6131_06_p333-337 4/5/06 10:28 AM Page 333 AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 22, Number 4, 2006, pp. 333 337 Mary Ann Liebert, Inc. Higher Risk of Hyperglycemia in HIV-Infected Patients Treated
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationHIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy
BRIEF COMMUNICATION HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy Authors Daniela Souza Araújo de Angelis 1 Adriana Fumie Tateno 1
More informationChanges in cellular HIV DNA levels during the MONET trial: 144 Weeks of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
Changes in cellular HIV DNA levels during the MONET trial: 144 Weeks of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs Anna Maria Geretti, Jose R Arribas, Johan Vingerhoets, Geraldine Foster, Sabine
More informationHIV-1 Protease and Reverse Transcriptase Mutation Patterns Responsible for Discordances Between Genotypic Drug Resistance Interpretation Algorithms
JAIDS Journal of Acquired Immune Deficiency Syndromes 33:8 14 2003 Lippincott Williams & Wilkins, Inc., Philadelphia Rapid Communication HIV-1 Protease and Reverse Transcriptase Mutation Patterns Responsible
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEconomic analysis of initial HIV treatment: efavirenz- versus indinavir-containing triple therapy Caro J J, O'Brien J A, Miglaccio-Walle K, Raggio G
Economic analysis of initial HIV treatment: efavirenz- versus indinavir-containing triple therapy Caro J J, O'Brien J A, Miglaccio-Walle K, Raggio G Record Status This is a critical abstract of an economic
More informationResearch Article Efficacy of Once Daily Darunavir/Ritonavir in PI-Na\ve, NNRTI-Experienced Patients in the ODIN Trial
AIDS Research and Treatment Volume 2015, Article ID 962574, 6 pages http://dx.doi.org/10.1155/2015/962574 Research Article Efficacy of Once Daily Darunavir/Ritonavir in PI-Na\ve, NNRTI-Experienced Patients
More informationCD21 CD24 CD38 CD27 CD27. IgD IgD. bm3+4. bm2. early bm5. bm2. bm1. late bm5. unswitched memory. switched memory. naive
SDC, Figure S1: The Bm1-Bm and the IgD/CD7 classifications of peripheral mature B cells. CD19 + B cells were analyzed with two double staining IgD/CD38 (Bm1-Bm classification) and IgD/CD7 (left panels).
More informationPharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2008.03220.x Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women Matthieu Roustit, 1,2 Malik Jlaiel, 1
More informationSECONDARY OBJECTIVES:
Study No.: 112 419 Title: Retrospective study using the NADIS database of the reasons for discontinuing the Abacavir-Lamivudine combination in HIV-infected patients treated by an antiretroviral regimen
More informationMedChem 401~ Retroviridae. Retroviridae
MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The
More informationAn Update On HIV Pharmacotherapy. Gonzalo M.L. Bearman MD,MPH Assistant Professor of Medicine Associate Hospital Epidemiologist
An Update On HIV Pharmacotherapy Gonzalo M.L. Bearman MD,MPH Assistant Professor of Medicine Associate Hospital Epidemiologist Outline Review HIV epidemiology HIV natural history Viral Dynamic and three
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationCONCISE COMMUNICATION
1688 CONCISE COMMUNICATION Vertical Transmission of Multidrug-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) and Continued Evolution of Drug Resistance in an HIV-1 Infected Infant Victoria A. Johnson,
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationDolutegravir-based anti-retroviral therapy is effective and safe in HIV infected paediatric patients
Bruzzese et al. Italian Journal of Pediatrics (2018) 44:37 https://doi.org/10.1186/s13052-018-0469-x RESEARCH Open Access Dolutegravir-based anti-retroviral therapy is effective and safe in HIV infected
More informationDidactic Series. HIV Drug-Drug Interactions: OTC and non-prescription medications. Kirsten B. Balano, PharmD UCSF School of Pharmacy February 26, 2015
Didactic Series HIV Drug-Drug Interactions: OTC and non-prescription medications Kirsten B. Balano, PharmD UCSF School of Pharmacy February 26, 2015 ACCREDITATION STATEMENT: University of California, San
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationDidactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching
Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University
More informationACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS
ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS Acquired immunodeficiency syndrome (AIDS ) is an infectious disease caused by a retrovirus, the human immunodeficiency virus(hiv). AIDS is
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationObstacles to successful antiretroviral treatment of HIV-1 infection: problems & perspectives
Review Article Indian J Med Res 119, June 2004, pp 217-237 Obstacles to successful antiretroviral treatment of HIV-1 infection: problems & perspectives Simon J. Potter, Choo Beng Chew*, Megan Steain, Dominic
More informationMilan, Italy. Received 15 March 2002; returned 22 July 2002; revised 12 September 2002; accepted 27 September 2002
Journal of Antimicrobial Chemotherapy (2003) 51, 135 139 DOI: 10.1093/jac/dkg016 Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More information